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Overexpression of Caspase-9 Triggers Its Activation and Apoptosis in Vitro
Aim To investigate the consequences of increased expression of cas-
pase-9: 1) whether the caspase-9 overexpression resulted in cell death 
through apoptosis, 2) whether apoptosis could be triggered in normal 
and tumor cells, and 3) what is the role of caspase-9 in the process.
Methods The caspase-9 fused to green fluorescent protein was ex-
pressed in primary cultures of anterior pituitary cells and of HeLa tu-
mor cells. The expressed caspase-9 and the number of apoptotic and 
necrotic cells were determined using fluorescence microscopy.
Results Overexpression of caspase-9 resulted in cell death of primary 
pituitary cells and HeLa cells. More than 94% of the cells died of apop-
tosis, which was triggered by the activation of caspase-9, since the cell 
deaths were prevented in the presence of caspase-9 specific inhibitor. 
HeLa cells were about 50% more resistant to apoptosis than pituitary 
cells.
Conclusions Caspase-9 overexpression and its activation leads to 
apoptosis. It occurs both in normal and tumor cells. Since the majority 
of cancer therapy treatments initiate apoptosis through the caspase-9 
activation, the modulation of caspase-9 expression may be exploited 
in designing new ways to control apoptosis in neurodegenerative or 
malignant diseases.
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There are two types of cell death: necrosis and 
apoptosis. Apoptosis or programmed cell death 
is a process which controls the number and the 
quality of cells (1). Caspases are proteases, which 
have a central role in triggering and executing 
apoptosis (2,3). The two major pathways of trig-
gering apoptosis are the intrinsic and extrinsic 
pathway (4). The main intrinsic pathway is char-
acterized by mitochondrial dysfunction, with the 
release of cytochrome c, activation of caspase-
9, and subsequently of caspase-3. The extrinsic 
pathway is activated at the cell surface through 
death receptor mediated activation of caspase-8 
or caspase-10, followed by caspase-3 activation. 
This pathway may be amplified by caspase-9 ac-
tivation (intrinsic pathway). Therefore, caspase-
9 is one of the main initiator caspases (5). Like 
the other members of the caspase family, it is syn-
thesized as an inactive zymogen and is activated 
through proteolytic processing. There are two 
main pathways for caspase-9 activation: within 
the apoptosome, a large protein complex, which 
consists of caspase-9, cytochrome c, and Apaf-1 
(6-8), or by proteolytic cleavage by a previously 
activated caspase, which involves its dimerization 
(9-11).
Among other processes, caspase-9 triggers 
apoptosis early in the development of nervous 
system (12,13). Failure of caspase-9 activation is 
also associated with the resistance for apoptosis 
in testicular tumors (14). In addition, the gene 
for caspase-9 maps to the locus disrupted in hu-
man tumors, a hotspot for loss of heterozygosity 
in several cancers, including neuroblastomas (15). 
A number of initial studies supported the claim 
that cancer therapy triggered apoptosis by acti-
vating the extrinsic pathway of apoptosis (16). 
Subsequently, there is compelling evidence that 
the majority of cytotoxic drugs initiate cell death 
by triggering the cytochrome c/Apaf-1/Caspase-
9-dependent pathway through the mitochondria 
(intrinsic pathway) (16). Embryonic stem cells 
with disrupted caspase-9 and thymocytes with 
disrupted Apaf-1 are resistant to cytotoxic drugs, 
but sensitive to death receptor triggering (extrin-
sic pathway) (13). In contrast, embryonic fibro-
blasts disrupted with caspase-8 are sensitive to 
cytotoxic drugs (17). The relative contributions 
of intrinsic and extrinsic pathways to apoptosis 
induced by cytotoxic drugs may also depend on 
the drug, dose, and kinetics (16). While there are 
data on the consequences of reduced amounts of 
caspase-9 in the cells, its overexpression has not 
been systematically investigated so far.
Here we report that caspase-9 overexpression 
triggers the activation of caspase-9 and apoptosis. 
It is likely that caspase-9 autoactivates itself un-
der these conditions, since the caspase-9 specific 
inhibitor prevents the cell deaths. The apoptosis 
due to overexpression seems to be a ubiquitous 
process, since it occurs in normal and in tumor 
transformed cells. HeLa cells are only 50% less 
sensitive to cell death due to caspase-9 overex-
pression than the primary pituitary cells.
Material and methods
Expression of fluorescent fusion proteins
Mammalian expression plasmids encoding fu-
sion proteins of green fluorescent protein (E), cy-
tochrome c (Cytc), and caspase-9 (Casp9) were 
constructed as is described in the following pub-
lications: Casp9E (18), CytcE (19), and Casp9 
(20). They were amplified using standard pro-
cedures and were introduced into the cells using 
LipofectAMINE PLUSTM reagent (Invitrogen, 
Carlsbad, CA, USA), according to the manufac-
turer’s instructions. The amount of DNA intro-
duced was 0.26 pmol and was kept constant in all 
experiments. Each type of DNA was introduced 
in at least 5 independent experiments; all types 
of fluorescent proteins were always expressed in 
parallel samples.
The optimal time between the introducing of 
DNA for fluorescent fusion proteins and detec-
tion of their expression was determined for each 
type of cells separately and was equal in all experi-
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ments. At least five cultures were performed for 
each experiment. The number of cells was kept 
constant: about 100 000 pituitary and 70 000 
HeLa cells for each sample. To decrease the vari-
ations between the samples due to the low num-
ber of fluorescent cells, the latter were counted 
throughout the sample.
Cell cultures
Primary cell cultures of pituitary cells from the 
anterior lobe were isolated from adult male rats 
(Wistar, body weight 200-300 g) as described by 
Ben-Tabou (21). Cells were placed on poly-L-
lys-coated coverslips, incubated in a rich nutritive 
medium composed of 80% Dulbecco’s Modi-
fied Eagle’s Medium with Nutrient Mixture F-
12 HAM (Invitrogen, Carlsbad, CA, USA), 9% 
Minimal essential medium with alpha modifi-
cation (MEM Alpha Medium; Sigma, St. Lou-
is, MO, USA), 0.4% D-glucose (Sigma), 25 mM 
N-hydroxyethylpiperazine-N’-2-ethanesulphon-
ic acid (Hepes, Sigma), 2 mM L-glutamine, and 
10% fetal bovine serum at 37°C, 5% CO2. HeLa 
cells were grown in MEM Alpha Medium (Sig-
ma), using standard procedures. After 24 hours, 
DNA was introduced into primary or HeLa 
cells, as described above.
When the cells were grown in the presence of 
an inhibitor z-LEHD.fmk (2 µmol/L, BioVision, 
Mountain View, CA, USA), it was added imme-
diately after the lipofection and was kept in the 
medium throughout the experiment. Apoptot-
ic and necrotic cells were dyed by annexin con-
jugated with Alexa Fluor 568 and Sytox Green 
(Invitrogen, Molecular Probes, Carlsbad, CA, 
USA), both according to the manufacturer’s in-
structions.
Image collection and statistical analyses
The images of fluorescent cells were captured us-
ing a Leica TCS SP confocal microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) with 
an oil immersion objective (40 × magnification 
and numerical aperture 1.25). Enhanced Green 
Fluorescence Protein (EGFP) was excited by ar-
gon laser at 488 nm and fluorescence was collect-
ed between 505 and 530 nm. The cells expressing 
the introduced DNA were identified by fluores-
cence microscopy (Olympus IX81, Olympus, 
Tokyo, Japan) through detection of EGFP.
The percentage of apoptotic cells in a sam-
ple was calculated by dividing the number of all 
apoptotic cells with the number of all dying cells 
in the sample. Apoptotic index (AI) was calculat-
ed as the ratio between the number of apoptotic 
cells and the number of all cells in the sample, ie, 
AI of fluorescent cells was the number of apop-
totic fluorescent cells divided by the number of 
all fluorescent cells in a sample.
The primary data (or the calculated AI) from 
at least five independent experiments were plot-
ted as box plot using Sigma Plot 10.0 (Systat 
Software, San Jose, CA, USA). Statistical analy-
ses were performed using Statistical Package for 
the Social Sciences, version 13.0.1 (SPSS Inc., 
Chicago, IL, USA) with a module for exact tests. 
Unpaired exact Wilcoxon test was used to com-
pare 2 groups, exact Kruskal-Wallis test to com-
pare more than 2 groups, and Fisher exact test to 
compare the calculated ratios of cells. We consid-
ered values of samples as statistically significant 
when P<0.01.
The survival rates of cells expressing fluores-
cently labeled caspase-9 (Casp9E+Casp9) were 
compared with those expressing cytochrome c 
(CytcE) by calculating ratios between the me-
dians of cell survival when CytcE was expressed 
and when Casp9E+Casp9 was expressed. The 
two ratios were plotted by Sigma plot 10.0.
Results
Overexpression of caspase-9 in culture cells
The cells expressing additional amounts of cas-
pase-9 were identified using detection of fluo-
rescent fusion proteins, either Casp9E or a fu-
sion between cytochrome c and EGFP (CytcE, 
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Figure 1A). When two different plasmids are in-
troduced into the cells simultaneously, there is 
a high probability that both plasmids will enter 
the same cell (22). The fluorescent fusion protein 
CytcE expressed on its own was used as a control 
to monitor the cell death due to the overexpres-
sion of a fluorescent fusion protein itself.
The morphology of some primary pituitary 
cells expressing additional amounts of caspase-9 
differed according to the construct introduced. 
Control cells, expressing the additional amounts 
of CytcE were morphologically indistinguishable 
from non-fluorescent cells (Figure 1A). The same 
was true for many cells expressing Casp9E. Some 
of these clearly showed apoptotic morphology. 
A typical vesicular structure of apoptotic cells 
was observed frequently in the samples where 
the part of the DNA for caspase-9 fusion protein 
was substituted by the plasmid expressing the full 
length caspase-9 only.
Overexpression of caspase-9 triggers cell death in 
primary pituitary cells
The relationship between the expression of flu-
orescent fusion proteins and cell survival is 
shown in Figure 1B. There were less fluorescent 
cells expressing Casp9E than the control Cyt-
cE (P<0.001, Kruskal-Wallis). Cells expressing 
the full length caspase-9 and Casp9E were more 
prone to death than those expressing the fluo-
rescent fusion protein Casp9E. Also, significant-
ly less cells survived when caspase-9 was overex-
pressed together with CytcE (CytcE+Casp9), 
compared with CytcE or with the equivalent 
amounts of CytcE expressed alone (data not 
shown). The survival of pituitary cells therefore 
seems to depend on the expression levels of cas-
pase-9.
Overexpression of caspase-9 triggers apoptosis 
in the cells
The pituitary cells overexpressing caspase-9 could 
have died either in the process of apoptosis or ne-
crosis. To distinguish between these possibilities, 
the cells were labeled with a fluorescent conju-
gate of annexin V (annexin V-568) (23) and the 
membrane impermeant dye Sytox Green, which 
detects necrotic cells (Figure 2A). Out of all dy-
ing cells, there were more than 94% of apoptot-
ic cells in all samples: about 98% in cells overex-
pressing cytochrome c and their non-fluorescent 
controls and 94% in cells overexpressing caspase-
9 in addition to cytochrome c (CytcE+Casp9) 
and their non-fluorescent controls. The differ-
Figure 1. Effects of overexpression of caspase-9 on cell survival. (A) 
Pituitary cells expressing fusion proteins cytochrome c-EGFP (Cyt-
cE), cytochrome c-EGFP and caspase-9 (CytcE+Casp9), caspase-
9-EGFP (Casp9E), and caspase-9 in addition to caspase-9-EGFP 
(Casp9E+Casp9). A typical morphology associated with apoptosis 
was rarely observed in the cells overexpressing CytcE; apoptotic cells 
were observed frequently when Casp9E+Casp9 were overexpressed. 
Bar: 5 μm. (B) The survival of pituitary cells depended on the con-
struct expressed; the differences in survival rates were statistically 
significant (P<0.001, Kruskal-Wallis test). Each box plot represents 
the results of 5 independent experiments; the thin line indicates the 
mean value.
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ence between the two samples was statistically 
significant (P<0.001, Fisher exact test). Howev-
er, we did not consider it practically significant, 
since the magnitude of the difference was very 
small. Therefore, almost all cell deaths due to 
caspase-9 overexpression occurred by apoptosis; 
necrosis did not contribute significantly to cell 
death.
To compare the incidence of apoptosis be-
tween samples expressing different amounts 
of caspase-9 we calculated the AI (Figure 2B). 
Median apoptotic index of cells expressing 
CytcE+Casp9 was 100% compared to 58% in 
cells overexpressing only CytcE (P<0.001, Fisher 
exact test).
The non-fluorescent cells were grown on the 
same coverslips as their fluorescent counterparts, 
but they did not express fluorescent fusion pro-
teins. Apoptotic indices for both control groups 
of CytcE and CytcE+Casp9 were about 0.1% 
(Figure 2C); more than 100 times lower than 
in the case of fluorescent cells. Median AI of the 
two groups (CytcE and CytcE+Casp9) differed 
by only 0.05%; the statistical significance was cal-
culated by Fisher exact test (P<0.001). Because 
the difference was very small, we did not consider 
the calculated statistical significance to be practi-
cally significant.
Overexpression of caspase-9 triggers its 
activation
Overexpression of caspase-9 may result in apop-
tosis because of autoactivation of caspase-9 or 
as a consequence of activation of a different cas-
pase. To distinguish between these possibilities, 
we investigated whether active caspase-9 is nec-
essary for cell death. Cells overexpressing fluores-
cent caspase-9 (Casp9E) or cytochrome c (Cyt-
cE) were treated with caspase-9 specific inhibitor 
z-LEHD.fmk. No statistically significant differ-
ence was observed when CytcE was grown in the 
presence or absence of the inhibitor and when 
caspase-9 was expressed in the presence of its in-
hibitor (P = 0.926, Kruskal-Wallis test, Figure 3).
Figure 2. Overexpression of caspase-9 triggers apoptosis in pitu-
itary cells. A) The percentage of apoptotic cells among all dead cells. 
There was a statistically significant difference between the cells 
overexpressing CytcE and CytcE+Casp9 from five independent ex-
periments (P<0.001, Fisher exact test). Because the magnitude of the 
difference was very small, we do not consider it practically significant. 
(CytcE: cytochrome c-EGFP, CytcE+Casp9: cytochrome c-EGFP and 
caspase-9). The thin line indicates the mean value. B) Apoptotic in-
dex (AI) of cells overexpressing fluorescent fusion proteins. AI was 
calculated as the ratio of the numbers of annexin labeled fluorescent 
cells and all f luorescent cells. The addition of caspase-9 to CytcE sig-
nificantly increased AI from 58% to 100% (medians; P<0.001 Fisher 
exact test). The thin line indicates the mean value. C) Apoptotic index 
of control cells, compared with those overexpressing fluorescent fu-
sion proteins. The non-fluorescent cells were grown on the same cov-
erslips as the fluorescent ones; however, they did not overexpress the 
fluorescent proteins. Although nonfluorescent cells predominated, the 
apoptotic index was more than 100-fold lower than in the case of their 
fluorescent counterparts. There was a statistically significant differ-
ence between CytcE and CytcE+Casp9 (P<0.001, Fisher exact test). 
Because of the small size of the difference, we do not consider that the 
calculated statistical difference was practically significant. The thin 
line indicates the mean value.
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Caspase-9 overexpression causes apoptosis in 
tumor cells
We introduced plasmids expressing both caspas-
es Casp9E+Casp9 and a control protein Cyt-
cE into HeLa cells, resilient malignant cells de-
rived from adenosquameous carcinoma of the 
cervix which are widely used in research (24). In 
the case of HeLa cells, the number of fluorescent 
cells that overexpressed Casp9E+Casp9 was sig-
nificantly lower than the number of cells that ex-
pressed CytcE (P = 0.008, unpaired Wilcoxon 
test, Figure 4A).
Similar to pituitary cells, overexpression of 
caspase-9 triggered apoptosis in HeLa cells (Fig-
ure 4B). Apoptotic index was significantly low-
er in cells with overexpressed CytcE than in cells 
with overexpressed Casp9E+Casp9 (P<0.001, 
Fisher exact test). To compare the resilience of 
primary and tumor transformed cells, we calcu-
lated the ratios between the surviving fluorescent 
cells overexpressing CytcE and Casp9E+Casp9 
(Figure 5). Pituitary cells were 16 times more 
likely to die and HeLa cells were about 8 times 
more likely to die when overexpressing caspase-9 
rather than cytochrome c.
Discussion
We first studied the effects of overexpression of 
caspase-9 on the cell survival in rat anterior pi-
tuitary cells. Apoptosis has an important role in 
remodeling of anterior pituitary, since the pitu-
itary has to respond continuously to transient 
but often repeated stimuli such as physiological 
and psychological stresses, throughout life (25). 
Figure 3. Activation of caspase-9 is necessary for the apoptosis 
due to its overexpression. The pituitary cells were grown in the pre-
sence of 2 μM z-LEHD.fmk, where appropriate (+z-LEHD.fmk), after 
the introduction of DNA for fluorescent fusion proteins. There are no 
statistically significant differences between the samples (P = 0.926, 
Kruskal-Wallis test). CytcE: cytochrome c-EGFP, Casp9E: caspase-
9-EGFP. The thin line indicates the mean value.
Figure 4. HeLa cells die of apoptosis due to caspase-9 overexpressi-
on. A) The number of fluorescent cells significantly decreases when 
Casp9E+Casp9 is introduced into the cells (P = 0.008, Wilcoxon test). 
CytcE: cytochrome c-EGFP, Casp9E+Casp9: caspase-9 in addition to 
caspase-9-EGFP. The thin line indicates the mean value. B) Apoptotic 
index was calculated from 5 independent experiments. In the case of 
the cells expressing Casp9E+Casp9, the apoptotic index increased 
significantly to 48%, from 4% when expressing CytcE (P<0.001, Fisher 
exact test). The thin line indicates the mean value.
Figure 5. Survival rates of the pituitary and HeLa cells expressing 
Casp9E+Casp9 and CytcE. All expression levels were normalized 
to expression levels of Casp9E+Casp9. CytcE: cytochrome c-EGFP 
(grey bars); Casp9E+Casp9: caspase-9 in addition to caspase-9-
EGFP (closed bars).
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Therefore, pituitary cells from the anterior lobe 
are likely to be a good model for studying apop-
tosis. We showed that overexpression of caspase-
9 caused cell death. Necrosis occurred in less than 
6% of apoptotic dying cells, both in cells overex-
pressing caspase-9 and the controls. The apopto-
sis initiation due to overexpression of caspase-9, 
was tested in pituitary cells and HeLa cells. Simi-
lar results were obtained from primary astrocytes, 
though there were on average less than 10 astro-
cytes expressing Casp9E (our unpublished data). 
Our results support the finding by Duan et al 
(20) that overexpression of caspase-9 increased 
the ratio of dying cancer cells MCF7, however in 
the case of MCF7, the cause of death was not in-
vestigated any further. We conclude that apop-
tosis initiation by overexpression of caspase-9 is 
ubiquitous, as it occurs in different types of cells, 
including tumor cells.
In this study, we overexpressed two com-
ponents of the apoptosome, cytochrome c, and 
caspase-9. Only the overexpression of caspase-9 
triggered apoptosis through the activation of cas-
pase-9, since the rates of cell death were equal in 
the cells overexpressing cytochrome c in the pres-
ence or absence of the caspase-9 specific inhibi-
tor. Cells that co-expressed caspase-9 and cyto-
chrome c had a higher survival rate than cells that 
expressed only caspase-9. Cytochrome c, which is 
not conjugated with heme (apocytochrome c), 
can inhibit the apoptosome formation in vitro 
(26). While we cannot rule out that CytcE has an 
inhibitory effect, this inhibition is not complete, 
since apoptosis is increased when caspase-9 is co-
expressed with CytcE. A possible explanation is 
that caspase-9 is activated directly by proteolytic 
processing of a caspase, without the formation 
of the apoptosome. Although there is a possibil-
ity that a caspase other than caspase-9 is activat-
ed first, the caspase-9 specific inhibitor z-LEHD.
fmk completely prevented apoptosis in transfect-
ed cells. The same inhibitor was not able to pre-
vent apoptosis triggered by rotenone (18). There-
fore, caspase-9 itself may trigger apoptosis by its 
overexpression. One possibility is that because of 
the higher expression levels, the molecules of cas-
pase-9 are brought closer together, which enables 
the dimerization necessary for their activation. 
This seems to be in contrast with the observation 
that it is difficult to achieve a dimerization of cas-
pase-9 in solutions, at least in vitro (27,28). On 
the other hand, caspase-9 is an exception among 
the caspases since it can be active even in its pro-
caspase (zymogen) form (27,29). If so, why is 
apoptosis not triggered by caspase-9 expressed 
in normal cells? There may be a balance between 
the expression levels of caspase-9 and its modula-
tors. This is supported by the recent discovery of 
a dose-dependent inhibition of caspase-9 by HS-
associated protein-1 (HAX-1) from cardiac my-
ocytes (30).
The amounts of expressed caspase-9 differ 
among the tissues of the body. There is more cas-
pase-9 mRNA in the ovaries and testes compared 
with the spleen, thymus, intestine, or colon (20). 
Therefore, different expression levels of caspase-
9 are likely to have a physiological role. It was re-
ported that too low levels of caspase-9 in tissues 
result in disturbances in the embryonic devel-
opment and cause death in mice (12). A lower 
amount of caspase-9 was established also in the 
brain of patients with Alzheimer disease (31). 
Therefore, the amount of expressed caspase-9 
must be highly regulated within the cells. A too 
low amount of this enzyme can result in neu-
rodegenerative diseases or malignancies, while 
too high an amount can cause programmed cell 
death. Even mild overexpression of caspase-9 
triggers the death of tumor transformed cells. 
The amount of expressed caspase-9 increases 3-
fold to substitute the lack of caspase-2 in caspase-
2 null mutants (32). Different expression levels 
of caspase-9 may be necessary for controlling cell 
quality and proliferation in the body.
Overexpression of caspases seems to be a 
common molecular mechanism for triggering 
apoptosis. Increased synthesis of caspase-2 and 
caspase-3 was found to precede apoptosis of some 
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leukemic and colon carcinoma cell lines after the 
application of etoposide (33); in fact the abili-
ty of the tumor cells to up-regulate the caspase-2 
and caspase-3 genes was related to the sensitivity 
of the cell lines to drug-induced apoptosis. Also, 
the treatment with both interferon-gamma and 
cytotoxic drugs increased caspase-8 expression 
and triggered apoptosis in the cell lines derived 
from the Ewing tumor (34). Since the majority 
of cancer therapy treatments initiate apoptosis 
through the activation of caspase-9 (16), it is im-
portant to study the ways of caspase-9 activation, 
which can be exploited to control apoptosis in 
neurodegenerative and malignant diseases.
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